ira.turovets@gmail.com

About ira.turovets@gmail.com

This author has not yet filled in any details.
So far ira.turovets@gmail.com has created 9 blog entries.
17 10, 2017

Eos Biosciences Announces Issuance of Additional U.S. Patent For Targeted Breast Cancer Therapy

October 17th, 2017|

Los Angeles, CA- October 17, 2017- Eos Biosciences, Inc., a bio-targeted nanomedicines company developing a novel nanobiologic particle drug delivery platform technology (Eosomes), and a proprietary oncology-specific product pipeline, announced that the U.S. Patent and Trademark Office has now issued Eos Biosciences a second patent, U.S. Patent No. 9,789,201, for Eos-001, the company’s HER3-targeted Eosome [...]

13 09, 2017

Eos Biosciences Announces Issuance of U.S. Patent for Novel Oncology Theranostic

September 13th, 2017|

Eos Biosciences announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,757,386, which covers composition of matter and method of use for Eos Biosciences’ theranostic product Eos-002, a HER3-targeted Eosome with manganese corrole payload. HER3 is over-expressed on many types of metastatic and drug-resistant solid tumors.

10 02, 2017

Eos Biosciences will attend the 2017 Biotechnology Innovation Organization (BIO)

February 10th, 2017|

1 06, 2016

Eos Biosciences will attend the 2016 Biotechnology Innovation Organization (BIO) International Convention

June 1st, 2016|

21 04, 2016

Eos Biosciences, Inc. recruited Thomas Plotts to join the company as its Chief Financial Officer

April 21st, 2016|

April 21, 2016 – Eos Biosciences, Inc. recruited Thomas Plotts to join the company as its Chief Financial Officer. Plotts previously served as Chief Financial Officer and Vice President, Finance at Los Angeles Biomedical Research Institute, a world-class independent biomedical research institute focused on the discover, causes and genetic underpinnings of rare, chronic and infectious diseases. [...]

29 12, 2015

Eos Biosciences, Inc. closed its Series A financing round in December, 2015, with follow-on participation from all of the investors in the company’s seed round.

December 29th, 2015|

4 01, 2015

Eos Biosciences, Inc. completed its seed financing round in January, 2015 and is now in the process of rounding out its Series A financing, already having secured follow-on participation from all of the investors in the company’s seed round.

January 4th, 2015|

Eos Biosciences, Inc. completed its seed financing round in January, 2015 and is now in the process of rounding out its Series A financing, already having secured follow-on participation from all of the investors in the company’s seed round.

5 05, 2014

Eos Biosciences, Inc. adds Peter Linsley, Ph.D. and Michael Kahn, Ph.D. to the company’s Science Advisory Board.

May 5th, 2014|

Eos Biosciences, Inc. adds Peter Linsley, Ph.D. and Michael Kahn, Ph.D. to the company’s Science Advisory Board. Dr. Linsley an expert in RNAi therapeutics, Oncology and Immunology is currently a Research Associate Member at the Benaroya Research Institute. Dr. Kahn has expertise in Oncology, Peptidomimetics and Molecular & Cell Biology and is currently Provost Professor [...]

26 12, 2013

Eos Biosciences, Inc. and Cedars-Sinai Medical Center sign a license agreement

December 26th, 2013|

Eos Biosciences, Inc. and Cedars-Sinai Medical Center sign a license agreement, providing Eos Biosciences with an exclusive world-wide license to a novel and innovative drug-targeting platform technology developed by Dr. Lali Medina-Kauwe at Cedars-Sinai Medical Center. The agreement covers nanopartical technology patent rights for use in the prevention, treatment or diagnosis of diseases.